22.01.2020 • News

BASF Upgrades Polyacrylates at Ludwigshafen

BASF Upgrades Polyacrylates at Ludwigshafen (c) BASF
BASF Upgrades Polyacrylates at Ludwigshafen (c) BASF

With a “single-digit million-euro” investment, BASF has improved the flexibility of its water-soluble polyacrylates plant at its Ludwigshafen, Germany, headquarters site and expanded capacity slightly. Details have not been provided.

The world’s largest chemical producer said the facility is now up and running and supplying customers in the household and commercial cleaning products, as well as in chemical and formulator industries.

"High-performance water-soluble polyacrylates and copolymers are an indispensable component of our customers' formulations. With this investment and our applications expertise, we are supporting our European customers in their efforts to boost their market growth with differentiated products," said Soeren Hildebrandt, senior vice president, Home Care, I&I and Industrial Formulators Europe.

BASF’s water-soluble polyacrylates and copolymers are marketed by its Care Chemicals operating division under the Sokalan brand name and have numerous applications in the household and commercial cleaning products industry for water softening and in various technical processes, for example to prevent fouling.

As dye transfer inhibitors, Sokalan branded products also protect fabrics from discoloration during washing. The narrow molecular weight distribution of the latest class of polyacrylates makes them highly effective as mineral dispersing agents, BASF said.

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read